 |
|
This slide deck covers newly released data in advanced breast cancer focusing on the following data releases:
Abstract S3-7: Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial
Abstract S4-8: First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC)
Abstract S5-5: A phase III, randomized, double-blind, placebo-controlled registration trial to evaluate the efficacy and safety of pertuzumab + trastuzumab + docetaxel vs. placebo + trastuzumab + docetaxel in patients with previously untreated HER2-positive metastatic breast cancer (CLEOPATRA)
Abstract S5-7: A phase 2, randomized, open-label, study of neratinib (HKI-272) vs lapatinib plus capecitabine for 2nd/3rd-line treatment of HER2+ locally advanced or metastatic breast cancer
Abstract P5-19-03: Albumin-bound paclitaxel (ab-pac) versus docetaxel for first-line treatment of metastatic breast cancer (MBC): Overall survival and safety analysis of a randomized phase II trial
View the downloadable slides
|
|
|
This activity is supported by Genentech.
|
 |
|
